Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.16% of ...
Standard BioTools (LAB) expects fourth quarter 2024 revenue of approximately $46.5M and full year 2024 revenue of approximately $174M. “The ...
In recent trading, Standard Biotools Inc (LAB) stock price has shown some volatility, fluctuating 13.19% over the last five trades and 1 ...
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue ...
Standard BioTools Inc. announced that its President and CEO, Dr. Michael Egholm, will present at the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2024, with his presentation ...
Investing.com -- Shares of Standard BioTools Inc. (NASDAQ: LAB) surged 30% following the company's announcement of preliminary fourth quarter revenue that exceeded market expectations. The life ...
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue ...
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback